On February 3, 2020 Boston Pharmaceuticalstoday reported the appointment of Dr. Craig T. Basson, M.D., Ph.D., as Chief Medical Officer (Press release, Boston Pharmaceuticals, FEB 3, 2020, View Source [SID1234553777]). Previously, Dr. Basson was Global Head of Translational Medicine (Cardiovascular and Metabolism) at Novartis for 10 years, where he led the team developing new global programs to translate basic findings into novel therapeutics.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As a highly-regarded scientist and drug developer, Craig’s experience in global translational medicine is uniquely suited to Boston Pharmaceuticals as we continue to evolve our pipeline," said Robert Armstrong, Ph.D., Chief Executive Officer and Co-Founder of Boston Pharmaceuticals. "His proven track record for innovation and drug development will support our mission of addressing unmet medical needs for larger patient populations."
"Boston Pharmaceuticals’ strategy of following the data and selectively advancing a portfolio of high value candidates into differentiated therapeutics excites me," said Dr. Basson. "I am thrilled to join Boston Pharmaceuticals at this time of important growth for the company and look forward to leveraging my experience to accelerate the development of the pipeline and to continuing to bring novel medicines to patients in need."
Dr. Basson was previously Global Head of Translational Medicine for the Cardiovascular and Metabolic Therapeutic Areas at Novartis Institutes for Biomedical Research. At Novartis, he co-led the Cardiovascular Metabolism (CVM) Disease Area Decision Board, oversaw the leadership of early clinical portfolio through Proof of Concept (PoC) and supported late phase clinical programs by indication expansion PoC studies and specialized clinical pharmacology and profiling studies. He has been involved in the development of a number of important and novel medicines for patients with cardiovascular disease, diabetes, and metabolic disorders.
Prior to Novartis, Dr. Basson was a Professor of Cardiology and Internal Medicine at Cornell University Medical College. He obtained an M.Sc. in Physiological Sciences at the University of Oxford and completed an M.D. and Ph.D. at Yale University. Dr. Basson serves as a scientific advisor to variousfor-profit and nonprofit organizations.